IP Library Granted Patent US 9,393,322
Granted Patent B2
US 9,393,322 · App. 14/510,921 · Granted Jul 19, 2016

Treating glaucoma, cardiovascular diseases, and renal diseases

Inventors: Eric M. Poeschla (Rochester, MN); Roman A. Barraza (Rochester, MN)
Assignee: Mayo Foundation for Medical Education and Research
A61K48/005A61K38/44C12N9/0083A61K38/00C12Y114/99001
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,393,322
App. No.
14/510,921
Granted
Jul 19, 2016
Kind
B2
Abstract

This document provides methods and materials related to treating glaucoma, ocular hypertension, cardiovascular diseases, and renal diseases. For example, this document provides isolated nucleic acid molecules and viral vectors (e.g., lentiviral vectors) containing isolated nucleic acid molecules. Methods for reducing intraocular pressure as well as symptoms and progression of cardiovascular and renal diseases also are provided.

Claims (8)

1. A method for reducing elevated intraocular pressure, said method comprising administering nucleic acid encoding a cyclooxygenase-2 polypeptide to an eye of a mammal under conditions effective to reduce intraocular pressure of said eye by at least 10 percent.

2. The method of claim 1 , wherein said mammal is a human.

3. The method of claim 1 , wherein said administering step comprises contacting said eye with a solution containing said nucleic acid encoding said polypeptide.

4. The method of claim 1 , wherein said method is effective to reduce said intraocular pressure by at least 20 percent.

5. The method of claim 1 , wherein said method is effective to reduce said intraocular pressure by at least 30 percent.

6. The method of claim 1 , wherein said nucleic acid encoding said polypeptide is administered using a viral vector.

7. The method of claim 6 , wherein said viral vector is a lentiviral vector.

8. The method of claim 1 , wherein said polypeptide is a human cyclooxygenase-2 polypeptide, and wherein said nucleic acid encoding said polypeptide is codon-optimized for use in mammalian cells.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2015
From: POESCHLA, ERIC M.; BARRAZA, ROMAN A.
To: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Reel/Frame 036346/0645 →
CONFIRMATORY LICENSE Recorded Oct 28, 2014
From: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 034068/0577 →
Continuity (4)
Continuation 13624383 · Sep 21, 2012
Continuation 12298431
Provisional Application 60795789 · Apr 28, 2006
Related Publication 20150031757A1 · Jan 29, 2015